scholarly journals The Fetal Origins of the Metabolic Syndrome: Can We Intervene?

2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Noelle Ma ◽  
Daniel B. Hardy
Keyword(s):  
Metabolic Syndrome ◽  
Molecular Mechanisms ◽  
Dietary Intervention ◽  
Critical Factor ◽  
Epidemiological Studies ◽  
Fetal Life ◽  
Fetal Origins ◽  
The Metabolic Syndrome ◽  
Neonatal Life

Epidemiological studies have suggested that metabolic programming begins during fetal life and adverse eventsin uteroare a critical factor in the etiology of chronic diseases and overall health. While the underlying molecular mechanisms linking impaired fetal development to these adult diseases are being elucidated, little is known about how we can intervene early in life to diminish the incidence and severity of these long-term diseases. This paper highlights the latest clinical and pharmaceutical studies addressing how dietary intervention in fetal and neonatal life may be able to prevent aspects of the metabolic syndrome associated with IUGR pregnancies.

scholarly journals Metabolic Syndrome. Particularities During SARS-CoV-2 Infection

2021 ◽  
Vol 28 (2) ◽  
pp. 119-125
Author(s):  
Ana-Maria CIOTI ◽  
Ioana Veronica GRAJDEANU ◽  
Anca Angela SIMIONESCU ◽  
Cristian Gabriel BEJAN ◽  
Ana Maria Alexandra STANESCU
Keyword(s):  
Metabolic Syndrome ◽  
Molecular Mechanisms ◽  
Health Hazard ◽  
Multiple Organ ◽  
Health Crisis ◽  
The Metabolic Syndrome ◽  
Significant Public Health ◽  
Organ Failures ◽  
Socioeconomic Consequences

The COVID-19 pandemic is a significant public health crisis as the coronavirus continues to rapidly spread with long-term socioeconomic consequences. Another malady, although non-transmissible, also a significant health hazard is the metabolic syndrome, which has widespread globally, being classified as an epidemic as the western lifestyle expands worldwide. The SARS-CoV-2 causes systemic inflammation similar to obesity; nevertheless, the coronavirus causes an unregulated rise in cytokine secretion, resulting in multiple organ failures and death. Increasing evidence demonstrates that obesity aggravates the COVID-19 disease and its mortality, the four most prevalent comorbidities of COVID-19 being hypertension, diabetes, cardiovascular, and respiratory disease, all of them tightly associated with obesity. This paper reviews the physiopathological processes that constitute the metabolic syndrome and the molecular mechanisms through which the coexistence of MetS can contribute to the pathogenicity of COVID-19 and an unfavorable outcome of the disease.

Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up

2011 ◽  
Vol 96 (5) ◽  
pp. 1271-1274 ◽  
Author(s):  
Miriam Hudecova ◽  
Jan Holte ◽  
Matts Olovsson ◽  
Anders Larsson ◽  
Christian Berne ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
The Metabolic Syndrome ◽  
Previous Diagnosis ◽  
Long Term Follow Up

scholarly journals Effects of Polyphenol Intake on Metabolic Syndrome: Current Evidences from Human Trials

2017 ◽  
Vol 2017 ◽  
pp. 1-18 ◽  
Author(s):  
Gemma Chiva-Blanch ◽  
Lina Badimon
Keyword(s):  
Metabolic Syndrome ◽  
Type Ii Diabetes ◽  
Randomized Trials ◽  
Virgin Olive Oil ◽  
Epidemiological Studies ◽  
Current Evidence ◽  
Aromatic Plants ◽  
Polyphenol Intake ◽  
Public Health Strategies

Metabolic syndrome (MetS) is a cluster of cardiovascular risk factors which severely increases the risk of type II diabetes and cardiovascular disease. Several epidemiological studies have observed a negative association between polyphenol intake and MetS rates. Nevertheless, there are relatively small numbers of interventional studies evidencing this association. This review is focused on human interventional trials with polyphenols as polyphenol-rich foods and dietary patterns rich in polyphenols in patients with MetS. Current evidence suggests that polyphenol intake has the potential to alleviate MetS components by decreasing body weight, blood pressure, and blood glucose and by improving lipid metabolism. Therefore, high intake of polyphenol-rich foods such as nuts, fruits, vegetables, seasoning with aromatic plants, spices, and virgin olive oil may be the cornerstone of a healthy diet preventing the development and progression of MetS, although there is no polyphenol or polyphenol-rich food able to influence all MetS features. However, inconsistent results have been found in different trials, and more long-term randomized trials are warranted to develop public health strategies to decrease MetS rates.

The metabolic syndrome in long-term cancer survivors, and important target for secondary preventive measures

2002 ◽  
Vol 28 (4) ◽  
pp. 195-214 ◽  
Author(s):  
Janine Nuver ◽  
Andries J Smit ◽  
Aleida Postma ◽  
Dirk Th Sleijfer ◽  
Jourik A Gietema
Keyword(s):  
Metabolic Syndrome ◽  
Cancer Survivors ◽  
Preventive Measures ◽  
The Metabolic Syndrome ◽  
Important Target

scholarly journals An Exploratory Analysis of Criteria for the Metabolic Syndrome and Its Prediction of Long-term Cardiovascular Outcomes

2005 ◽  
Vol 162 (5) ◽  
pp. 438-447 ◽  
Author(s):  
Cynthia J. Girman ◽  
Jacqueline M. Dekker ◽  
Thomas Rhodes ◽  
Giel Nijpels ◽  
Coen D. A. Stehouwer ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Cardiovascular Outcomes ◽  
Exploratory Analysis ◽  
The Metabolic Syndrome

P4402Effect of carnitine supplementation on progression of carotid plaque in the metabolic syndrome: the ECoM study

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
A Johri ◽  
M F Hetu ◽  
D K Heyland ◽  
J E Herr ◽  
P Norman ◽  
...  
Keyword(s):  
Risk Factors ◽  
Metabolic Syndrome ◽  
Animal Studies ◽  
International Diabetes Federation ◽  
Epidemiological Studies ◽  
Analysis Of Covariance ◽  
Atherosclerosis Progression ◽  
The Metabolic Syndrome ◽  
Significant Difference ◽  
Elevated Glucose

Abstract Background/Introduction L-carnitine (L-C) has been investigated as a potential therapy for cardiovascular (CV) disease, but its direct effects on human atherosclerosis are unknown. Epidemiological studies suggest a possible reduction of CV risk factors following treatment, whereas animal studies have shown that L-C may increase pro-atherogenic metabolites. Purpose The purpose of this study was to determine whether L-C therapy led to atherosclerosis progression or regression by direct quantification of carotid atherosclerotic lesions in patients with metabolic syndrome (MetS). Methods This study was a Phase 2, prospective, parallel, double blinded, randomized, placebo-controlled, two-center trial. MetS was defined according to the International Diabetes Federation harmonized definition, where presence of any 3 of the 5 following risk factors constituted a diagnosis: elevated waist circumference; elevated triglycerides; reduced HDL or treated; elevated blood pressure or treated; elevated glucose or HbA1c or treated. Participants with a baseline carotid total plaque volume (TPV) ≥50 mm3 were randomized to placebo or 2 g L-C daily for 6 months. Plaque progression was quantified by 3D carotid ultrasound for change in TPV and reduction in vessel lumen area (% area stenosis, Fig. 1). Absolute differences were assessed on the raw scale, while percent change on the log scale. Analysis of covariance (ANCOVA) was used to assess within- and between-arm differences. Results Of the 177 participants randomized, 157 completed the study (L-C n=76, placebo n=81). No statistically significant difference between arms was found in the primary outcome (TPV). However, there was progression of plaque stenosis in the treatment arm: the L-C group had an increase in stenosis of 9.8% (p=0.01) higher than the placebo arm, and a 2.7% (p=0.03) greater absolute change. Total cholesterol and LDL levels (0.10 mmol/L and 0.05 mmol/L, respectively) were higher in the intervention arm compared to the placebo arm (−0.06 mmol/L and −0.07 mmol/L). Figure 1 Conclusions We observed progression of atherosclerosis with L-C therapy compared to placebo in patients with MetS. The clear lack of benefit of L-C therapy in this population raises serious concerns for its further use as a potential therapy. Given its association with pro-atherogenic metabolites our study offers further understanding of the atherosclerotic process. Acknowledgement/Funding Heart and Stroke Foundation of Canada

scholarly journals Cardiovascular and Metabolic Consequences of Liver Transplantation: A Review

Medicina ◽  
2019 ◽  
Vol 55 (8) ◽  
pp. 489
Author(s):  
Plotogea ◽  
Ilie ◽  
Sandru ◽  
Chiotoroiu ◽  
Bratu ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Liver Transplantation ◽  
De Novo ◽  
Current Knowledge ◽  
Morbidity And Mortality ◽  
High Morbidity ◽  
Term Survival ◽  
The Metabolic Syndrome ◽  
Acute Liver Disease

Liver transplantation (LT) is considered the curative treatment option for selected patients who suffer from end-stage or acute liver disease or hepatic malignancy (primary). After LT, patients should be carefully monitored for complications that may appear, partially due to immunosuppressive therapy, but not entirely. Cardiovascular diseases are frequently encountered in patients with LT, being responsible for high morbidity and mortality. Patients with underlying cardiovascular and metabolic pathologies are prone to complications after the transplant, but these complications can also appear de novo, mostly associated with immunosuppressants. Metabolic syndrome, defined by obesity, hypertension, dyslipidemia, and hyperglycemia, is diagnosed among LT recipients and is aggravated after LT, influencing the long-term survival. In this review, our purpose was to summarize the current knowledge regarding cardiovascular (CV) diseases and the metabolic syndrome associated with LT and to assess their impact on short and long-term morbidity and mortality.

Sign in / Sign up

Export Citation Format

Share Document